Date and time: Tue 03-Nov-2020, 12:45-13:45
Programme theme(s): Prevention and early detection
Programme session type(s): Live session, Sponsored session
Interest for: Allied Health Professionals, Clinicians, Nurses, Scientists, Trainees
Speakers will discuss various aspects of MSI testing for Lynch Syndrome and ICI therapy. Also, preliminary data will be shown on determining MSI status in liquid biopsies (ctDNA) to assess ICI therapy response and relapse in MSI-High colorectal cancer. They will also discuss the clinical utility of MSI testing from a pathologist’s perspective.
Join this session to learn more about the MSI testing:
Precision Oncology for Immune Checkpoint Inhibitor Therapy with OncoMate MSI Dx System. – Jeff Bacher, Sr Research Scientist 2, Promega
Clinical Utility of MSI testing for Lynch syndrome and anti-PD1 immunotherapy: The Pathologists Perspective. – Dr Anca Oniscu, Consultant Pathologist and Clinical Lead for Molecular Pathology, Laboratory Medicine, Edinburgh Royal Infirmary.
Speaker: Dr Anca Oniscu,Edinburgh Royal Infirmary